ReviewCurrent oncology reports2025
Who Truly Benefits From First-Line Intensification in EGFR-Mutant NSCLC?
Michele Maffezzoli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ReviewCurrent oncology reports2025
Michele Maffezzoli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.